Core Viewpoint - Tianyu Co., Ltd. focuses on serving large multinational pharmaceutical companies and original research drug companies, aiming to deepen its "customer first" strategic goal [1] Group 1: Business Strategy - The company has provided active pharmaceutical ingredients (APIs) for 8 original research drug varieties and aims to add 1-2 new commercialized APIs annually with original research drug companies [1] - The company seeks to strengthen existing partnerships with original research clients while expanding its customer base to enhance its competitive advantage in APIs [1] Group 2: Strategic Partnerships - Tianyu has established long-term stable strategic partnerships with internationally renowned pharmaceutical companies such as Novartis, Sanofi, and Daiichi Sankyo [1] - The scope of cooperation has expanded from sartans APIs to non-sartan APIs, off-patent drugs, and innovative drug CDMO projects, indicating an increase in both depth and breadth of collaboration [1]

Summary of Industry Reports Industry: Pharmaceutical and Biotechnology Key Points from Document 1 1. **Raw Material Supply Changes**: The supply of raw materials is accelerating, with a focus on subsequent volume and price changes [1] 2. **Global GLP-1 Landscape**: The global GLP-1 landscape is continuously evolving, and Chinese companies are still pursuing international expansion [1] 3. **Small Nucleic Acid Sector**: Leading companies are gradually entering the small nucleic acid field, with market progress expected to drive the development of supporting industrial chains [1] 4. **Retail Pharmaceutical Market Outlook**: The retail pharmaceutical market is expected to improve by Q4 2025, with an enhanced positioning of chain pharmacies [1] 5. **Value of Oral Immunomodulatory Drugs**: Emphasis on the market value of oral immunomodulatory drugs [1] 6. **Investment Recommendations**: Recommended companies include Chuaning Biological, with attention to Lianbang Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, as well as synthetic biology companies [1] 7. **CXO Order Trends**: Positive trends in CXO orders and rising prices for safety evaluation orders, with recommendations for Yinos and Zhaoyan New Drug, and recommendations for Weiya Biological and Puris [1] Key Points from Document 2 1. **Small Nucleic Acids Breakthrough**: Continuous breakthroughs in small nucleic acids, with ongoing progress in external authorizations by Chinese companies, recommending Yuekang Pharmaceutical and Sunshine Novo [2] 2. **Self-Immunity Field**: Focus on breakthroughs in oral directions and difficult-to-treat areas like UC/IBD, recommending Yahong Pharmaceutical and Yifang Biological [2] 3. **GLP-1 Weight Loss Authorizations**: Recommendations for Zhongsheng Pharmaceutical in the GLP-1 weight loss field, with attention to Lianbang Pharmaceutical and Shiyao Group [2] 4. **ZAP-X Radiation Therapy Equipment**: Initiation of domestic clinical research for ZAP-X radiation therapy equipment, recommending Baiyang Pharmaceutical [2] 5. **Policy Support for Brain-Computer Interface Technology**: Support for the development of invasive brain-computer interfaces, recommending Meihao Medical and Botuo Biological, with accelerated approvals for non-invasive devices, focusing on Xiangyu Medical and Kefu Medical [2] 6. **High-Value Medical Device Exports**: Breakthroughs in exports of high-value medical consumables, with attention to Chunli Medical, Aikang Medical, Nanwei Medical, and Baixin An [2] 7. **AI in Healthcare**: Accelerated applications of AI in healthcare, reshaping application scenarios and bringing changes in industrial chain value, recommending Anbiping and focusing on Yuyue Medical and Meinian Health [2] 8. **Chain Pharmacy Industry**: Industry consolidation in chain pharmacies, with policy support for enhanced positioning, recommending Yifeng Pharmacy and Laobaiqing, with attention to Yixintang [2]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The supply of raw materials in the pharmaceutical industry is accelerating, with a focus on subsequent price and volume changes [2] - The global GLP-1 market is evolving, with Chinese companies continuing to explore international opportunities [3] - Leading companies are gradually entering the small nucleic acid field, which is expected to drive the development of supporting industrial chains [4] - The retail pharmaceutical market is showing positive trends, with chain pharmacies enhancing their positioning [5] - The value of oral immunosuppressive drugs is gaining attention [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 1.47 percentage points in the last week, ranking 15th among 31 primary industry indices [18] - The pharmaceutical industry index increased by 0.14% during the same period [18] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index has a current PE (TTM) of 37.31, above the five-year historical average of 31.11 [40] 3. Recent Research Achievements - The report highlights various deep-dive studies on topics such as the growth of biological agents and oral medications, and the impact of policies on the inhalation drug industry [44] 4. Recent Industry Policies and News - The National Healthcare Security Administration issued a notice to accelerate the cultivation and application of new scenarios in the medical insurance sector [46] - Recent approvals for clinical trials of new drugs by major pharmaceutical companies, including AstraZeneca and Hengrui Medicine, indicate ongoing innovation in the industry [47][48] 5. Key Companies and Profit Forecasts - The report includes profit forecasts for several companies, with recommendations for stocks such as Yuyuan Pharmaceutical and Sunshine Nuohua, indicating a positive outlook for their performance [9]

Core Viewpoint - The company has signed a framework agreement with the People's Government of Huachuan County, Jiamusi City, Heilongjiang Province, to establish a modern digital factory for traditional Chinese medicine and raw material drug production, aligning with the national "big health" industry development strategy [1] Group 1 - The agreement was signed on February 6, 2026, in Beijing [1] - The project aims to enhance production capacity and core competitiveness in the traditional Chinese medicine and raw material drug industry [1] - Funding for the project will primarily come from the company's self-raised funds [1]

Group 1: Gold and Silver Market Outlook - A Reuters survey indicates that gold prices are expected to reach a new high of $4,746.50 per ounce by 2026, driven by geopolitical uncertainties and strong central bank purchases, marking a significant increase from last year's forecast of $4,275 [1] - The average price expectation for silver in 2026 has also been raised to $79.50 per ounce, up from $50 in the previous year's survey [1] Group 2: Currency and Economic Analysis - The strong US dollar is exerting downward pressure on gold and silver prices, with analysts suggesting that if the dollar's rebound continues, it may further impact gold prices negatively [2] - UBS forecasts a 10% increase in global stock markets by the end of the year, with a focus on diversification into markets like China, Japan, and Europe, driven by strategic autonomy and fiscal expansion [3] - Mitsubishi UFJ reports that the Japanese yen has fallen to a near two-week low due to election expectations, with potential for continued selling pressure as confidence in the ruling party's stability grows [4] - Goldman Sachs warns of upward fiscal risks in Japan ahead of the upcoming elections, suggesting that unless the Bank of Japan accelerates interest rate hikes, the yen may weaken further [6] Group 3: Sector-Specific Insights - Zhongtai Securities expresses a positive outlook on the raw material pharmaceutical sector, highlighting innovations in small nucleic acids and ADC toxins as catalysts for growth [7] - CITIC Securities recommends focusing on automotive companies with strong cost transfer capabilities and global layouts, as rising raw material prices are expected to pressure profit margins in the first quarter of 2026 [8] - Galaxy Securities identifies two main paths for AI-driven benefits: enhancing platform efficiency and improving production efficiency through content and tools, suggesting a focus on internet stocks and AI-related applications [9]

Market Overview - Major indices opened lower, with the Shanghai Composite Index down 0.66%, Shenzhen Component down 0.96%, and ChiNext down 1.02% [1] - The decline was led by sectors such as precious metals, photovoltaic, and semiconductor chips [1] Index Performance - Shanghai Composite Index: 4075.03, down 0.66%, with 460 gainers and 1493 losers [2] - Shenzhen Component: 14020.84, down 0.96%, with 396 gainers and 2202 losers [2] - ChiNext Index: 3277.72, down 1.02%, with 182 gainers and 1099 losers [2] External Market Influence - U.S. stock markets continued to experience style rotation, with the Nasdaq down over 1% for the second consecutive day [3] - The S&P 500 Index fell by 0.51%, while the Dow Jones Industrial Average rose by 0.53% [3] - Chinese concept stocks were affected, with the Nasdaq Golden Dragon China Index down 1.95% [3] Sector Insights - CICC forecasts breakthroughs in large model technology in areas such as reinforcement learning and contextual engineering by 2026 [4] - Zhongtai Securities expresses a positive outlook on the raw material drug sector, highlighting the potential of innovative drug tracks like small nucleic acids and peptides [5] - CITIC Securities recommends focusing on automotive companies with strong cost transfer capabilities and global layouts due to rising raw material prices impacting profit margins [7]

Group 1 - The core viewpoint of the article highlights ongoing investment opportunities in the pharmaceutical sector, particularly in thematic areas such as brain-computer interfaces, AI healthcare, and small nucleic acids, with a strategic focus on the raw materials pharmaceutical sector [1] - The biopharmaceutical ETF (512290) has seen a continuous net inflow of over 460 million yuan for 10 consecutive days, indicating strong market interest [1] - The raw materials pharmaceutical sector is currently at a price bottom, with expectations of recovery driven by rising chemical prices and the introduction of new business lines such as small nucleic acids and peptides, which may lead to a mid-term positive cycle [1] Group 2 - The CS Biomedicine Index (930726), which the biopharmaceutical ETF tracks, selects listed companies involved in biotechnology, pharmaceuticals, and related life sciences from the Shanghai and Shenzhen markets to reflect the overall performance of the biopharmaceutical sector [1] - The rising prices of chemical products are expected to create cost pressures that will benefit integrated leading companies with cost advantages along the industry chain [1] - Innovative therapies such as GLP-1, small nucleic acid chronic disease drugs, and ADCs are generating significant global demand for APIs and intermediates, providing a second growth curve for raw material pharmaceutical companies [1]

Core Insights - The Supreme People's Court released the "Intellectual Property Court Annual Report (2025)", focusing on preventing "involution" competition in industries and regulating monopolistic behaviors in essential sectors like pharmaceuticals and construction materials [1][2] - The report emphasizes the importance of fair competition and the need for judicial efficiency in antitrust cases, highlighting the court's role in fostering a healthy industrial environment [1][2] Group 1: Involution Competition - The court aims to combat "involution" competition by aligning with national interests and promoting fair competition, thereby creating conditions for orderly industrial development [1] - The report mentions successful resolution of patent disputes in the optical lens sector, encouraging companies to focus on innovation and healthy competition [1] Group 2: Antitrust Enforcement - Since its establishment, the court has accepted 347 antitrust cases, concluding 292, with 66 cases recognized as monopolistic [2] - In 2025, 49 cases were concluded, with 15 identified as monopolistic, indicating ongoing judicial efforts to enhance antitrust effectiveness [2] Group 3: Regulation of Key Sectors - The report highlights the regulation of monopolistic behaviors in essential sectors, including a case involving a horizontal monopoly agreement among raw material pharmaceutical companies, which aims to lower production costs for finished drugs [2] - The court has also addressed horizontal monopoly agreements in the cement industry, supporting administrative penalties to maintain fair competition [2] Group 4: Platform Regulation - The report discusses the regulation of large platforms abusing market dominance, particularly in mobile payment services, to protect consumer rights and promote interconnectivity [2] - The court's actions in the "shared electric bike" case marked a significant step in breaking down administrative monopolies, promoting a unified national market [2]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The pharmaceutical and biotechnology sector is expected to experience a cyclical recovery in raw material prices for animal health products in 2026, following a prolonged decline due to oversupply and weak downstream demand [5][49] - Heparin and iodine contrast agent raw materials are currently at the bottom of their price cycles, with heparin prices declining sharply in Q4 2023 due to market pressures, while iodine prices have seen a recent recovery driven by strong demand from other industries [6][51] Summary by Sections Industry Trends - The pharmaceutical and biotechnology sector saw a decline of 0.39% in the third week of January 2026, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th among 31 sub-industries [7][58] - The offline pharmacy segment experienced the highest increase, rising by 9.66%, while the medical research outsourcing segment faced the largest decline, dropping by 3.96% [7][61] Price Trends - The average price of florfenicol has decreased from the range of 400-700 RMB/kg to a recent range of 100-200 RMB/kg, indicating a significant drop to historical lows [5][47] - Heparin API prices are stabilizing, while iodine raw material prices are expected to rise in 2025 due to previous supply constraints [51][55] Recommended Stocks - Monthly recommended stocks include WuXi AppTec, 3SBio, and CSPC Pharmaceutical Group, among others [8] - Weekly recommended stocks include Kanglong Chemical, WuXi AppTec, and Aopumai [8]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The pharmaceutical and biotechnology sector is expected to experience a cyclical recovery in raw material prices for animal health products in 2026, following a prolonged decline due to oversupply and weak downstream demand [5][49] - Heparin and iodine contrast agent raw materials are currently at the bottom of their price cycles, with heparin prices declining sharply in Q4 2023 due to market pressures, while iodine prices have seen a recent recovery driven by strong demand from other industries [6][51] Summary by Sections Industry Trends - The pharmaceutical and biotechnology sector saw a decline of 0.39% in the third week of January 2026, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th among 31 sub-industries [7][58] - The offline pharmacy segment experienced the highest increase, rising by 9.66%, while the medical research outsourcing segment faced the largest decline, dropping by 3.96% [7][61] Price Trends - The average price of florfenicol has decreased from the range of 400-700 RMB/kg to a recent range of 100-200 RMB/kg, indicating a significant drop to historical lows [5][47] - Heparin raw material prices have stabilized after a period of decline, while iodine raw material prices are expected to rise again in 2025 due to increased demand [51][55] Recommended Stocks - Monthly recommended stocks include WuXi AppTec, 3SBio, and CSPC Pharmaceutical Group, while weekly recommendations feature companies like Kanglong Chemical and Yao Ming He Lian [8]